Home › Blood Cancers › North Carolina
Blood Cancers clinical trials in North Carolina
24 studies for Blood Cancers are looking for participants at sites in North Carolina.
Cities in North Carolina
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Duke Cancer Center Cary, Cary
- Duke University Medical Center, Durham
- East Carolina University, Greenville
- and 4 more
RecruitingObservational study
All ages · All sexes · Updated Oct 5, 2026 · NCT04242095Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074), Cary
- University of North Carolina at Chapel Hill ( Site 0040), Chapel Hill
- Duke Cancer Center ( Site 0028), Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- and 6 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 27, Chapel Hill
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Novant Health Weisiger Cancer Institute, Charlotte
RecruitingObservational study
Ages 0 and older · All sexes · Updated Sep 2, 2026 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of North Carolina, Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Atrium Health Levine Cancer Center, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Recruiting
Ages 60 and older · All sexes · Updated Aug 14, 2026 · NCT06296368A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06823167PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Lineberger Cancer, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT06665100ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
- Levine Cancer Insitute, Charlotte
Recruiting
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07203534Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
- 2400 Pratt Street, Durham
Recruiting
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06532773Implementation of an Oral Chemotherapy Adherence Intervention
- UNC Chapel Hill, Chapel Hill
Recruiting
Ages 21 and older · All sexes · Updated Jul 8, 2026 · NCT06989489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of North Carolina at Chapel Hill, Chapel Hill
- Levine Children's Hospital, Charlotte
- Duke University Medical Center, Durham
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingObservational studyHealthy volunteers welcome
Ages 15 and older · All sexes · Updated Jun 30, 2026 · NCT06897137Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Duke University Medical Center, Duke Cancer Center, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Duke Blood Cancer Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
- Duke University Health System, Durham
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT06731504A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- Levine Cancer Institute, Charlotte
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 3, 2025 · NCT06119685Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Carolina-Levine Children's Hospital, Charlotte
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.